Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

Table 4

Comparison of the incidence of adverse reactions (n (%)).

Group	Hypertension	Hand-foot syndrome	Anemia	Reactive cutaneous capillary hyperplasia	Chest pain	Hemoptysis	Total incidence
STG	3 (6.82)	3 (6.82)	2 (4.55)	0 (0.00)	2 (4.55)	3 (2.27)	29.55% (13/44)
CTG	1 (2.27)	0 (0.00)	1 (2.27)	3 (6.82)	0 (0.00)	0 (0.00)	11.36% (5/44)
X^2							4.470
P							<0.05